Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Sara Tolaney MD, MPH
Sara M. Tolaney MD, MPH Advisory Board
Benjamin Anderson MD, FACS
Benjamin O. Anderson MD, FACS Advisory Board
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
See All Experts
featured
Published in Oncology

Journal Scan / Research · December 20, 2018

Sequential or Concurrent FOLFOXIRI/Bevacizumab vs FOLFOX/Bevacizumab in Metastatic Colorectal Cancer

The Oncologist

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

The Oncologist
Phase 2 Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab vs FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)
Oncologist 2018 Dec 14;[EPub Ahead of Print], HI Hurwitz, BR Tan, JA Reeves, H Xiong, B Somer, HJ Lenz, HS Hochster, F Scappaticci, JF Palma, R Price, JJ Lee, A Nicholas, N Sommer, J Bendell

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated